Kit comprising KL-6 protein on exosomes for use in auxiliary diagnosis of interstitial lung diseases and use

By detecting the binding of KL-6 protein and CA125 in exosomes, the problem of insufficient sensitivity of serum KL-6 detection is solved, and high specificity and high sensitivity diagnosis of interstitial pneumonia is achieved, helping to identify disease progression in the early stage and improve treatment efficiency.

WO2024235147A1PCT designated stage expired Publication Date: 2024-11-21THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV (GUANGZHOU RESPIRATORY CENT) +2
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/092551
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-15
Filing Date
2024-05-11
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

In the prior art, the early diagnosis of interstitial pneumonia is difficult to accurately complete, and the sensitivity and specificity of serum KL-6 detection are insufficient, so it is impossible to effectively identify the type of disease and progression status.

Method used

By detecting the level of KL-6 protein in exosomes, combining CA125 protein, and using special kits and methods, we can achieve auxiliary diagnosis of interstitial pneumonia, reduce the impact of interfering substances in the serum, and improve the specificity and sensitivity of the diagnosis. .

Benefits of technology

It significantly improves the diagnostic sensitivity and specificity of interstitial pneumonia, can identify patients in the progression of fibrosis earlier, avoid treatment delays, and provides a stable detection method for the study of exosomal proteins.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024092551_21112024_PF_FP_ABST
    Figure CN2024092551_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention belongs to the technical field of protein detection, and particularly relates to a detection kit comprising a KL-6 protein on exosomes for use in the auxiliary diagnosis of interstitial lung diseases. The detection method comprises: treating an exosome sample with a sample treatment liquid, then reacting the exosomes containing a KL-6 protein in the sample with a magnetic bead coating substance working liquid and a luminescent substance-labeled antibody working liquid to form an immune complex, and detecting the luminescence intensity by using a chemiluminescence method and calculating the concentration value. In the present invention, a method of using a KL-6 protein on exosomes extracted from blood in combination with CA125 or alone in the diagnosis of interstitial pneumonia is first provided. The method reduces the influence of free KL-6 proteins and other interfering substances in serum. Compared with a traditional serum detection kit, the kit of the present invention has a higher specificity and sensitivity, and has an important clinical value and promotion prospects in the auxiliary diagnosis of interstitial lung diseases.
Need to check novelty before this filing date? Find Prior Art

Description

A kit and application of KL-6 protein on exosomes for auxiliary diagnosis of interstitial lung disease Technical Field

[0001] The present invention belongs to the technical field of protein detection, and specifically relates to a kit, a detection method and an application of KL-6 protein on exosomes for auxiliary diagnosis of interstitial lung diseases. Background Art

[0002] Interstitial lung disease (ILD) is a general term for a diverse group of clinical and pathological entities characterized by diffuse parenchymal and alveolar inflammation and interstitial fibrosis, with clinical manifestations including dyspnea on activity, diffuse infiltrates on chest X-rays, restrictive ventilation, decreased diffusing capacity (DLCO), and hypoxemia. Early diagnosis and treatment of interstitial pneumonia can improve patient prognosis. Therefore, in addition to established diagnostic methods such as lung CT, pulmonary function tests, blood gas analysis, bronchoscopy, and lung biopsy, serological tests related to the development and prognosis of ILD have become a research hotspot.

[0003] Siallylated carbohydrate antigen-6 (KL-6) is considered a promising serological marker. Currently, many studies have shown that KL-6 is significantly correlated with the occurrence, progression, drug efficacy, and prognosis of ILD lesions. However, serum KL-6 testing still exhibits insufficient clinical sensitivity and specificity. Therefore, the development of interstitial pneumonia detection reagents with higher sensitivity and specificity is an important clinical need.

[0004] Exosomes are extracellular vesicles with diameters ranging from 40 nm to 160 nm, with an average diameter of 100 nm. They are formed by invagination of the cytoplasmic membrane and fusion with other intracellular vesicles and organelles. A variety of cells can secrete exosomes under both normal and pathological conditions, but the relationship between exosomal proteins and interstitial pneumonia remains understudied. KL-6 is a single transmembrane protein expressed by the MUC1 gene. In theory, membrane proteins can be retained on exosomes during exosome formation and secreted into the circulation through exosomes, potentially offering significant clinical value in serological diagnosis. However, the expression levels of these proteins on exosomes and their correlation with interstitial pneumonia remain unreported.

[0005] Therefore, establishing a method to accurately detect lung disease-related proteins on exosomes to determine the disease type and progression status of interstitial pneumonia has important clinical and research value.

[0006] Summary of the Invention

[0007] The purpose of the present invention is to provide a KL-6 protein detection kit and a detection method on exosomes, which can be used independently or in combination for auxiliary diagnosis of interstitial lung disease.

[0008] In a first aspect, the present application provides a use of KL-6 protein on exosomes in the preparation of a kit for diagnosing lung diseases, using the following technical solution:

[0009] A use of KL-6 protein on exosomes in the preparation of a kit for diagnosing lung diseases.

[0010] Furthermore, KL-6 on exosomes is used as an interstitial lung disease marker for the diagnosis of interstitial pneumonia or other lung diseases.

[0011] KL-6 protein is primarily expressed on the surface of type II pneumocytes. When interstitial pneumonia occurs, the basement membrane of the lungs is damaged, and type II pneumocytes proliferate to repair the damage, leading to increased KL-6 production and entry into the blood through the damaged basement membrane. It exists in the blood as free KL-6 protein and KL-6 protein contained in extracellular vesicles (primarily exosomes). Research has found that testing for KL-6 protein in exosomes in the blood has a higher clinical compliance rate. Testing for exosome KL-6 reduces the impact of free KL-6 protein in the serum (present in both healthy and diseased populations) and other endogenous serum interfering substances.

[0012] In a second aspect, the present application provides an application of KL-6 and CA125 on exosomes in combination for the preparation of a kit for diagnosing lung diseases, using the following technical solution:

[0013] A combined use of KL-6 and CA125 on exosomes in the preparation of a kit for diagnosing lung diseases.

[0014] Furthermore, a protein combination of KL-6 and CA125 on exosomes is used as an interstitial lung disease marker for the diagnosis of interstitial pneumonia or other lung diseases.

[0015] By adopting the above technical solution, high expression of CA125 on exosomes is associated with interstitial pneumonia fibrosis or severe pneumonia. The combined detection of exosome KL-6 and exosome CA125 can effectively diagnose patients in the advanced stage of fibrosis, which helps to provide effective treatment earlier and avoid treatment delays.

[0016] In a third aspect, the present application provides a kit for diagnosing lung diseases, which adopts the following technical solution:

[0017] A kit for diagnosing lung diseases, comprising a sample processing solution, magnetic beads coated with a capture antibody, a detection antibody labeled with a luminescent substance, a luminescent substrate, and a protein calibrator; wherein the capture antibody is a KL-6 capture antibody, and the detection antibody is a KL-6 detection antibody. In this application, both the KL-6 capture antibody and the KL-6 detection antibody are antibodies that specifically bind to KL-6.

[0018] A kit for diagnosing lung diseases includes a sample processing solution, magnetic beads coated with a capture antibody, a detection antibody labeled with a luminescent substance, a luminescent substrate, and a protein calibrator. The capture antibody is a CA125 capture antibody, and the detection antibody is a CA125 detection antibody. Both the CA125 capture antibody and the CA125 detection antibody in this application are antibodies that specifically bind to CA125.

[0019] By adopting the above technical solution, using exosome KL-6 for independent detection, or using exosome KL-6 and exosome CA125 for combined detection, patients in the advanced stage of fibrosis can be effectively diagnosed, which helps to provide effective treatment earlier and avoid treatment delays.

[0020] Preferably, the sample processing liquid is a lysis-type sample processing liquid, which includes the following raw materials in weight percentage: 0.5-2% disodium hydrogen phosphate dodecahydrate, 0.5-2% sodium dihydrogen phosphate dihydrate, 0.5-3% NaCl, 0.5-3% BSA, 0.05-1% Triton X-100, 0.1-2% anionic surfactant, 0.1-5% zwitterionic surfactant, 0.1-2% Tween-20, 0.02-0.1% EDTA-2Na, 0.05-0.2% sodium azide, and the rest is water, pH 7.4.

[0021] The anionic surfactant is at least one of sodium lauryl sulfate (SDS), sodium lauryl sarcosine (NLS), and lithium lauryl sulfate (SLS).

[0022] The zwitterionic surfactant is at least one of CHAPS, sodium lauroamphoacetate, sodium cocoamphoacetate, CHAPSO, SB3-14, SB3-12, SB3-10, and SB3-8.

[0023] Preferably, the sample processing liquid is a non-lytic sample processing liquid, which includes the following raw materials in weight percentage: 0.5-2% disodium hydrogen phosphate dodecahydrate, 0.5-2% sodium dihydrogen phosphate dihydrate, 0.5-3% NaCl, 0.5-3% BSA, 0.2-2% zwitterionic surfactant, 0.1-2% Tween-20, 0.02-0.1% EDTA-2Na, 0.05-0.2% sodium azide, and the rest is water, pH 7.4.

[0024] The zwitterionic surfactant is at least one of SB3-14, sodium lauroamphoacetate, sodium cocoamphoacetate, SB3-12, SB3-10, and SB3-8.

[0025] In a fourth aspect, the present application provides a method for detecting the protein content in exosomes using the above-mentioned kit, which adopts the following technical solution:

[0026] The above kit is used for the method of detecting the protein content on exosomes, and the steps are as follows: before the exosome sample to be tested is detected, the exosome sample to be tested is pretreated, and the exosome sample to be tested is mixed with a sample treatment solution to obtain a pretreated exosome sample to be tested.

[0027] After the exosome sample is pretreated with sample processing solution, the exosomes containing KL-6 (or CA125) protein in the sample react with the magnetic bead coating working solution and the luminescent-labeled antibody working solution to form an immune complex. The luminescence intensity is detected by chemiluminescence and the concentration value is calculated.

[0028] In a specific embodiment, the kit is used for detecting the content of KL-6 (or CA125) protein on exosomes, and the specific steps are as follows:

[0029] (1) Pre-treating the exosome sample to be tested: mixing the exosome sample to be tested with the sample treatment solution for reaction;

[0030] (2) mixing the pretreated exosome sample to be tested obtained in step (1) with the magnetic bead coating working solution to obtain a magnetic bead-exosome / antigen complex;

[0031] (3) mixing the magnetic bead-exosome / antigen complex obtained in step (2) with the detection antibody of the luminescent labeled antibody working solution to obtain a magnetic bead-exosome / antigen-detection antibody complex;

[0032] (4) The magnetic bead-exosome / antigen-detection antibody complex obtained in step (3) is mixed with a luminescent substrate to react, and the luminescence intensity is detected.

[0033] (5) Using the standard curve method, the protein content in the exosome sample to be tested is calculated based on the luminescence intensity detected in step (4).

[0034] In a specific embodiment, in step (1), the volume ratio of the exosome sample to be tested to the sample processing solution is 1:(2-30).

[0035] For example, in step (1), the volume ratio of the exosome sample to be tested to the sample processing solution is 1:2, 1:5, 1:10, 1:12, 1:15, 1:18, 1:19, 1:20, 1:22, 1:25, 1:28 or 1:30.

[0036] In a specific embodiment, the reaction time of the pretreatment in step (1) is 1-120 min. Preferably, the reaction time is 1-10 min.

[0037] For example, the reaction time is 1 min, 2 min, 3 min, 4 min, 5 min, 6 min, 7 min, 8 min, 9 min or 10 min, etc.

[0038] In a specific embodiment, the reaction temperature of the pretreatment in step (1) is 25-42°C; preferably, the reaction temperature is 35-40°C.

[0039] For example, the reaction temperature is 35°C, 36°C, 37°C, 38°C, 39°C, 40°C, etc.

[0040] In a specific embodiment, the reaction time in step (2) and step (3) is 1-120 min, preferably, the reaction time is 5-15 min.

[0041] For example, the reaction time is 5 min, 6 min, 7 min, 8 min, 9 min, 10 min, 11 min, 12 min, 13 min, 14 min, and 15 min.

[0042] In a specific embodiment, the reaction temperature of step (2) and step (3) is 25-42°C, preferably, the reaction temperature is 35-40°C.

[0043] For example, the reaction temperature is 35°C, 36°C, 37°C, 38°C, 39°C, or 40°C.

[0044] In the above steps, a non-lytic sample processing solution is used, and the treated sample reacts with the magnetic bead coating to obtain a magnetic bead-exosome KL-6 antigen complex; a lytic sample processing solution is used, and the treated sample reacts with the magnetic bead coating to obtain a magnetic bead-KL-6 antigen complex.

[0045] When using the non-lysing sample treatment solution in this application to treat samples, the mixed sample must be incubated at the same time. When using the lysing sample pretreatment solution to pretreat the exosome sample, the next step can be performed without incubation.

[0046] In the present application, the exosome sample to be tested can be prepared from any one of the test samples: whole blood, serum, plasma, bronchoalveolar lavage fluid or urine.

[0047] The preparation method of the exosome sample to be tested in this application is any one of a fully automatic exosome extraction instrument or a manual extraction method (such as centrifugation, kit method, ultrafiltration method, magnetic bead immunoassay). Preferably, a fully automatic exosome extraction instrument or a kit method is used.

[0048] In some common exosome extraction methods (such as the kit method, magnetic bead immunoassay, and a fully automatic instrument extraction method), an eluent is often required to elute the exosomes from the adsorption carrier. These eluents are mainly solutions containing high concentrations of salt ions or surfactants, which cause the exosomes to dehydrate and easily aggregate. At the same time, the conformation of the proteins on the exosomes may also change. These factors will lead to poor accuracy and reproducibility of exosome protein detection results, making them unsuitable for clinical diagnosis. Studies have found that dilution of exosome samples with sample diluent can effectively improve the detection signal-to-noise ratio, but it requires a long reaction time and cannot be used for automated detection. On this basis, by combining sample processing solutions with a specific concentration range, the reaction time can be further shortened, effectively improving detection efficiency and the detection signal-to-noise ratio, thereby achieving fully automated detection of exosome proteins.

[0049] By pre-treating the exosome samples with sample processing fluid, the detection accuracy can be further improved, and no additional incubation time is required, which can greatly shorten the detection time.

[0050] In a specific embodiment, the preparation method of capture antibody-coated magnetic beads (also called magnetic bead coating) is as follows:

[0051] Magnetic bead activation: Add 5-20 mg of magnetic beads (magnetic bead concentration 5-20 mg / mL) to 1 mL of magnetic bead activation buffer (containing an aqueous solution of 1% MES by mass), add 25 μL of 20 mg / mL EDC solution (final concentration 0.5 mg / mL) and 25 μL of 40 mg / mL NHS solution (final concentration 1.0 mg / mL), react at room temperature for 15-120 minutes to activate the magnetic beads, and then remove the supernatant by magnetic separation.

[0052] Antibody Coupling: Resuspend the activated magnetic beads (5-20 mg / mL) in 1 mL of magnetic bead coupling buffer (1% MES in water). Add 100-300 μg of the KL-6 capture antibody to be coated (final concentration approximately 100-300 μg / mL). Incubate at room temperature for 1-2 hours to obtain a solution containing the magnetic bead-antibody conjugate.

[0053] Blocking: Add 100 μL of blocking agent (1% bovine serum albumin in water) to the solution containing the magnetic bead-antibody conjugate, at a volume ratio of 1:0.1. Incubate at room temperature for 1-4 hours. After magnetic separation and removal of the supernatant, add 1 mL of magnetic bead diluent to obtain capture antibody-coated magnetic beads. The magnetic bead diluent consists of PBS buffer containing 1% BSA and 0.1% proclin 300.

[0054] Preparation of magnetic bead coating working solution: Dilute the capture antibody-coated magnetic beads with magnetic bead coating diluent to a target concentration. The concentration after dilution is in the range of 0.1-1.5 mg / mL, with a particularly preferred concentration of 0.3-0.8 mg / mL.

[0055] The main components of the magnetic bead coating dilution solution are: TRIS 0.05-0.1%, NaCl 0.9-3.0%, BSA 1-3%, Tween-20 0.1-0.5%, sodium azide 0.1%, and the rest is water, pH 7.5.

[0056] The preparation method of the luminescent-labeled detection antibody (also called a marker) is as follows:

[0057] Preparation of acridinium ester stock solution: Acridinium ester was dissolved in anhydrous DMSO to prepare acridinium ester stock solution (final concentration 2.5 mg / ml).

[0058] Preparation of acridinium ester working solution: Take 10 μL of acridinium ester stock solution (final concentration 2.5 mg / ml), add 90 μL of anhydrous DMSO and dilute 10 times to prepare acridinium ester working solution (final concentration 0.25 mg / ml).

[0059] Labeling reaction: Dilute 200-400 μg of KL-6 detection antibody to 300 μL with 0.2 M NaHCO3 (pH = 9.0) solution (final antibody concentration 0.66-1.33 mg / mL), add 10 μL of acridinium ester working solution (final concentration approximately 0.008 mg / mL), wrap with tin foil, and label at room temperature for 0.5-2 hours.

[0060] Quench the reaction: add 100 μL of labeling termination buffer and mix at room temperature for 30-120 minutes; the buffer is formulated as a 0.2 M NaHCO3 solution containing 10% lysine, pH 9.0.

[0061] Purification: Purify the labeled antibody using a desalting column, collect the acridine-labeled protein fraction and adjust the concentration to obtain the luminescent-labeled detection antibody.

[0062] Preparation of luminescent labeled antibody working solution (also called marker working solution): dilute the luminescent labeled detection antibody with marker diluent to a target concentration of 0.05-1.00 μg / mL, preferably 0.1-0.6 μg / mL.

[0063] The main components of the marker diluent are: MES 0.05-0.1%, NaCl 0.9-3.0%, BSA 1-3%, Tween-20 0.1-0.5%, sodium azide 0.1%, and the rest is water, pH 6.5.

[0064] In the method for preparing a detection antibody labeled with a luminescent substance, the luminescent substance can be any one of acridine ester, alkaline phosphatase, and horseradish peroxidase.

[0065] In summary, this application includes at least one of the following beneficial technical effects:

[0066] 1. This application provides a method for the auxiliary diagnosis of interstitial lung disease using the exosome protein KL-6. Compared with serum KL-6 detection, the exosome KL-6 protein reduces the influence of free KL-6 protein and other interfering substances in the serum. Compared with traditional serum KL-6 detection kits, it has higher specificity and sensitivity and has good promotion prospects.

[0067] 2. This application provides two sample pretreatment methods: non-lytic and lytic, which reduce the impact of components in the eluate on exosome protein detection, effectively shorten the detection time, and facilitate the realization of fully automated detection of exosome proteins;

[0068] 3. This application provides for the first time a method for the combined use of exosome proteins KL-6 and CA125 for the auxiliary diagnosis of interstitial lung disease, which has important clinical value in the auxiliary diagnosis of interstitial lung disease;

[0069] 4. This application establishes a method for detecting KL-6 protein on exosomes, achieving stable detection of proteins on exosomes, which is of great value for the research of exosome proteins. BRIEF DESCRIPTION OF THE DRAWINGS

[0070] FIG1 is a bar graph comparing the test results of healthy subjects' samples and ILD patient samples in Test Example 2.

[0071] FIG2 is a ROC curve diagram of serum KL-6 and exosomal KL-6 in Test Example 3. DETAILED DESCRIPTION

[0072] To make the application easier to understand, the application will be described in further detail below in conjunction with Examples. These Examples serve only as illustrations and are not limited to the scope of application of the application. Within the scope of the technical concept of the application, multiple simple variations can be carried out to the technical scheme of the application, and these simple variations all belong to the protection scope of the application. The raw materials or components used in the application can be obtained by commercial means or conventional methods unless otherwise specified.

[0073] Definitions of abbreviations and key terms in this embodiment:

[0074] Example 1

[0075] A method for detecting KL-6 protein on exosomes comprises the following steps:

[0076] (1) Preparation steps of magnetic bead coating:

[0077] Magnetic bead activation: To 1 mL of magnetic bead activation buffer (containing an aqueous solution of 1% MES by mass), add 10 mg of magnetic beads (magnetic bead concentration 10 mg / mL), add 25 μL of 20 mg / mL EDC solution (final concentration 0.5 mg / mL) and 25 μL of 40 mg / mL NHS solution (final concentration 1.0 mg / mL), react at room temperature for 30 min to activate the magnetic beads, and then remove the supernatant by magnetic separation.

[0078] Antibody Coupling: Resuspend the activated magnetic beads (10 mg / mL) in 1 mL of magnetic bead coupling buffer (1% MES in water). Add 200 μg of the KL-6 capture antibody to be coated (final concentration approximately 200 μg / mL). Incubate at room temperature for 2 h to obtain a solution containing the magnetic bead-antibody conjugate.

[0079] Blocking: Add 100 μL of blocking agent (a 1% bovine serum albumin solution) to the solution containing the magnetic bead-antibody conjugate, at a volume ratio of 1:0.1. Incubate at room temperature for 2 hours. After magnetic separation and removal of the supernatant, add 1 mL of magnetic bead diluent to obtain capture antibody-coated magnetic beads (KL-6 magnetic beads). The magnetic bead diluent consists of PBS buffer containing 1% BSA and 0.1% proclin 300.

[0080] Preparation of magnetic bead coating working solution: Dilute KL-6 magnetic bead coating with magnetic bead coating diluent to obtain a 0.5 mg / mL magnetic bead coating working solution; the formula of the magnetic bead coating diluent is TRIS 0.1%, NaCl 2%, BSA 3%, Tween-20 0.5%, sodium azide 0.1%, and the remainder is water, pH 7.5.

[0081] (2) Preparation steps of marker-detection antibody complex:

[0082] Preparation of acridinium ester stock solution: Acridinium ester was dissolved in anhydrous DMSO to prepare acridinium ester stock solution (final concentration 2.5 mg / ml).

[0083] Preparation of acridinium ester working solution: Take 10 μL of acridinium ester stock solution (final concentration 2.5 mg / ml), add 90 μL of anhydrous DMSO and dilute 10 times to prepare acridinium ester working solution (final concentration 0.25 mg / ml).

[0084] Labeling reaction: Dilute 300 μg of KL-6 detection antibody to 300 μL with 0.2 M NaHCO3 (pH = 9.0) solution (final antibody concentration 1 mg / mL), add 10 μL of acridinium ester working solution (final concentration approximately 0.008 mg / ml), wrap with tin foil, and label at room temperature for 0.5 h.

[0085] Quench the reaction: add 100 μL of labeling termination buffer and mix at room temperature for 30 minutes; the buffer is a 0.2 M NaHCO 3 solution containing 10% lysine, pH 9.0.

[0086] Purification: Use a desalting column to purify the labeled antibody, collect the acridine-labeled protein fraction and adjust the concentration to obtain the luminescent-labeled detection antibody (KL-6 detection antibody acridine lipid label).

[0087] Preparation of luminescent-labeled antibody working solution (acridinium lipid marker working solution): Dilute the luminescent-labeled detection antibody (KL-6 detection antibody acridinium lipid marker) with acridinium lipid marker diluent to obtain an acridinium lipid marker working solution with a concentration of 0.4 μg / mL; the formula of the acridinium lipid marker diluent is: MES 0.1%, NaCl 2%, BSA 3%, Tween-20 0.1%, sodium azide 0.1%, and the remainder water, pH 6.5.

[0088] (3) Exosome sample pretreatment steps:

[0089] After extracting exosomes using the kit method, the exosome samples were pretreated: 10 μL of exosome sample was mixed with 190 μL of sample treatment solution and then incubated at 37°C for 5 min.

[0090] The sample processing liquid is a non-lytic sample processing liquid, which includes the following raw materials in weight percentage: 0.6% disodium hydrogen phosphate dodecahydrate, 0.6% sodium dihydrogen phosphate dihydrate, 0.9% NaCl, 1% BSA, 0.4% SB3-14, 0.1% Tween-20, 0.05% EDTA-2Na, 0.1% sodium azide, and the rest is water, pH 7.4.

[0091] (4) Detection and calculation of KL-6 content in the exosome sample to be tested:

[0092] Take 20 μL of the pretreated sample, add 50 μL of the magnetic bead coating working solution, mix well and incubate at 37°C for 5 minutes, then perform magnetic separation, wash to remove unbound substances, and remove the supernatant to obtain the magnetic bead-exosome complex.

[0093] Add 50 μL of luminescent labeled antibody working solution (acridinium lipid labeling working solution) to the reaction cup containing the magnetic bead-exosome complex, mix well and incubate at 37°C for 5 minutes, then perform magnetic separation, wash to remove unbound substances, and remove the supernatant to obtain the magnetic bead-exosome-detection antibody complex.

[0094] Add 100 μL of AE pre-stimulation solution and 100 μL of stimulation solution to the reaction cup containing the magnetic bead-exosome-detection antibody complex. Mix thoroughly and measure the maximum luminescence intensity. A standard curve is constructed based on the luminescence intensity of the standard sample. The KL-6 content in the sample is calculated using this standard curve.

[0095] Example 2

[0096] The main difference from Example 1 is that the sample processing liquid used is different.

[0097] The sample treatment solution is a non-lytic sample treatment solution, which includes the following raw materials in weight percentage: 1.0% disodium hydrogen phosphate dodecahydrate, 1.0% sodium dihydrogen phosphate dihydrate, 0.5% NaCl, 2% BSA, 0.5% sodium lauroamphoacetate, 0.2% Tween-20, 0.05% EDTA-2Na, 0.1% sodium azide, and the remainder is water, pH 7.4.

[0098] Example 3

[0099] The main difference from Example 1 is that the sample processing liquid used is different.

[0100] The sample treatment solution is a non-lytic sample treatment solution, which includes the following raw materials in weight percentage: 0.5% disodium hydrogen phosphate dodecahydrate, 0.5% sodium dihydrogen phosphate dihydrate, 0.5% NaCl, 0.5% BSA, 0.2% sodium cocoamphoacetate, 0.5% Tween-20, 0.02% EDTA-2Na, 0.05% sodium azide, and the remainder is water, pH 7.4.

[0101] Example 4

[0102] The main difference from Example 1 is that the sample processing liquid used is different.

[0103] The sample treatment solution is a non-lytic sample treatment solution, which includes the following raw materials in weight percentage: 2% disodium hydrogen phosphate dodecahydrate, 2% sodium dihydrogen phosphate dihydrate, 0.8% NaCl, 3% BSA, 1% sodium cocoamphoacetate, 0.5% Tween-20, 0.1% EDTA-2Na, 0.2% sodium azide, and the remainder is water, with a pH of 7.4.

[0104] Example 5

[0105] A method for detecting KL-6 protein on exosomes comprises the following steps:

[0106] (1) Preparation steps of magnetic bead coating:

[0107] Magnetic bead activation: To 1 mL of magnetic bead activation buffer (containing an aqueous solution of 1% MES by mass), add 10 mg of magnetic beads (magnetic bead concentration 10 mg / mL), add 25 μL of 20 mg / mL EDC solution (final concentration 0.5 mg / mL) and 25 μL of 40 mg / mL NHS solution (final concentration 1.0 mg / mL), react at room temperature for 30 min to activate the magnetic beads, and then remove the supernatant by magnetic separation.

[0108] Antibody Coupling: Resuspend the activated magnetic beads (10 mg / mL) in 1 mL of magnetic bead coupling buffer (1% MES in water). Add 200 μg of the KL-6 capture antibody to be coated (final concentration approximately 200 μg / mL). Incubate at room temperature for 2 h to obtain a solution containing the magnetic bead-antibody conjugate.

[0109] Blocking: Add 100 μL of blocking agent (a 1% bovine serum albumin solution) to the solution containing the magnetic bead-antibody conjugate, at a volume ratio of 1:0.1. Incubate at room temperature for 2 hours. After magnetic separation and removal of the supernatant, add 1 mL of magnetic bead diluent to obtain capture antibody-coated magnetic beads (KL-6 magnetic beads). The magnetic bead diluent consists of PBS buffer containing 1% BSA and 0.1% proclin 300.

[0110] Preparation of magnetic bead coating working solution: Dilute KL-6 magnetic bead coating with magnetic bead coating diluent to obtain a 0.5 mg / mL magnetic bead coating working solution; the formula of the magnetic bead coating diluent is TRIS 0.1%, NaCl 2%, BSA 3%, Tween-20 0.5%, sodium azide 0.1%, and the remainder is water, pH 7.5.

[0111] (2) Preparation steps of marker-detection antibody complex:

[0112] Preparation of acridinium ester stock solution: Acridinium ester was dissolved in anhydrous DMSO to prepare acridinium ester stock solution (final concentration 2.5 mg / ml).

[0113] Preparation of acridinium ester working solution: Take 10 μL of acridinium ester stock solution (final concentration 2.5 mg / ml), add 90 μL of anhydrous DMSO and dilute 10 times to prepare acridinium ester working solution (final concentration 0.25 mg / ml).

[0114] Labeling reaction: Dilute 300 μg of KL-6 detection antibody to 300 μL with 0.2 M NaHCO3 (pH = 9.0) solution (final antibody concentration 1 mg / mL), add 10 μL of acridinium ester working solution (final concentration approximately 0.008 mg / ml), wrap with tin foil, and label at room temperature for 0.5 h.

[0115] Quench the reaction: add 100 μL of labeling termination buffer and mix at room temperature for 30 minutes; the buffer is a 0.2 M NaHCO 3 solution containing 10% lysine, pH 9.0.

[0116] Purification: Use a desalting column to purify the labeled antibody, collect the acridine-labeled protein fraction and adjust the concentration to obtain the luminescent-labeled detection antibody (KL-6 detection antibody acridine lipid label).

[0117] Preparation of luminescent-labeled antibody working solution (acridinium lipid marker working solution): Dilute the luminescent-labeled detection antibody (KL-6 detection antibody acridinium lipid marker) with acridinium lipid marker diluent to obtain an acridinium lipid marker working solution with a concentration of 0.4 μg / mL; the formula of the acridinium lipid marker diluent is: MES 0.1%, NaCl 2%, BSA 3%, Tween-20 0.1%, sodium azide 0.1%, and the remainder water, pH 6.5.

[0118] (3) Exosome sample pretreatment steps:

[0119] After extracting exosomes using the kit method, the exosome sample was pretreated: 10 μL of exosome sample was mixed with 190 μL of sample treatment solution, mixed and reacted at 37°C for 5 min, and vortexed to mix thoroughly.

[0120] The sample processing solution is a lysis-type sample processing solution, which includes the following raw materials in weight percentage: 0.6% disodium hydrogen phosphate dodecahydrate, 0.6% sodium dihydrogen phosphate dihydrate, 0.9% NaCl, 1% BSA, 1% Triton X-100, 0.2% sodium dodecyl sulfate (SDS), 1% CHAPS, 0.1% Tween-20, 0.05% EDTA-2Na, 0.1% sodium azide, and the remainder is water, with a pH of 7.4.

[0121] (4) Detection and calculation of KL-6 content in the exosome sample to be tested:

[0122] Take 20 μL of the pretreated sample, add 50 μL of the magnetic bead coating working solution, mix well and react at 37°C for 5 minutes, then perform magnetic separation, wash to remove unbound substances, and remove the supernatant to obtain the magnetic bead-antigen complex.

[0123] Add 50 μL of luminescent labeled antibody working solution (acridinium lipid labeling working solution) to the reaction cup containing the magnetic bead-antigen complex, mix well and react at 37°C for 5 minutes, then perform magnetic separation, wash to remove unbound substances, and remove the supernatant to obtain the magnetic bead-antigen-detection antibody complex.

[0124] Add 100 μL of AE pre-stimulation solution and 100 μL of stimulation solution to a reaction cup containing the magnetic bead-antigen-detection antibody complex. Mix thoroughly and measure the maximum luminescence intensity. A standard curve is constructed based on the luminescence intensity of the standard sample. Calculate the KL-6 content in the sample using this curve.

[0125] Example 6

[0126] The main difference from Example 5 is that the sample processing liquid used is different.

[0127] The sample processing solution is a lysis-type sample processing solution, which includes the following raw materials in weight percentage: 0.5% disodium hydrogen phosphate dodecahydrate, 0.5% sodium dihydrogen phosphate dihydrate, 0.5% NaCl, 2% BSA, 0.5% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 0.5% SB3-8, 0.2% Tween-20, 0.05% EDTA-2Na, 0.1% sodium azide, and the remainder is water, with a pH of 7.4.

[0128] Example 7

[0129] The main difference from Example 5 is that the sample processing liquid used is different.

[0130] The sample processing solution is a lysis-type sample processing solution, which includes the following raw materials in weight percentage: 0.5% disodium hydrogen phosphate dodecahydrate, 0.5% sodium dihydrogen phosphate dihydrate, 0.5% NaCl, 0.5% BSA, 0.05% Triton X-100, 0.2% sodium lauryl sarcosinate (NLS), 0.5% sodium lauroamphoacetate, 0.1% Tween-20, 0.02% EDTA-2Na, 0.05% sodium azide, and the remainder is water, pH 7.4.

[0131] Example 8

[0132] The main difference from Example 5 is that the sample processing liquid used is different.

[0133] The sample processing solution is a lysis-type sample processing solution, which includes the following raw materials in weight percentage: 1% disodium hydrogen phosphate dodecahydrate, 1% sodium dihydrogen phosphate dihydrate, 0.9% NaCl, 3% BSA, 1% Triton X-100, 0.2% sodium lauryl sarcosine (NLS), 1% CHAPS, 2% Tween-20, 0.1% EDTA-2Na, 0.2% sodium azide, and the remainder is water, with a pH of 7.4.

[0134] Example 9

[0135] The main difference from Example 1 is that the capture antibody and detection antibody used are different.

[0136] The capture antibody used in this example is a CA125 capture antibody, and the detection antibody is a CA125 detection antibody.

[0137] Comparative Example

[0138] Comparative Example 1:

[0139] The difference between this comparative example and Example 1 is that no pretreatment is performed on the sample.

[0140] Comparative Example 2:

[0141] The difference between this comparative example and Example 1 is that PBS buffer is used to pretreat the sample.

[0142] The PBS buffer solution includes the following raw materials in weight percentage: NaCl 0.8%, KCl 0.02%, potassium dihydrogen phosphate 0.144%, dipotassium hydrogen phosphate 0.024%, and the rest is water, with a pH of 7.4.

[0143] Comparative Example 3:

[0144] The difference between this comparative example and Example 1 is that a commercially available sample diluent is used to pretreat the exosome sample.

[0145] The manufacturer of the sample diluent is Aimejie Technology Co., Ltd., product number: ICT-647.

[0146] Comparative Example 4:

[0147] The difference between this comparative example and Example 5 is that no pretreatment is performed on the sample.

[0148] Comparative Example 5:

[0149] The difference between this comparative example and Example 5 is that PBS buffer was used to pretreat the sample.

[0150] The PBS buffer solution includes the following raw materials in weight percentage: NaCl 0.8%, KCl 0.02%, potassium dihydrogen phosphate 0.144%, dipotassium hydrogen phosphate 0.024%, and the rest is water, with a pH of 7.4.

[0151] Comparative Example 6:

[0152] The difference between this comparative example and Example 5 is that a commercially available sample diluent is used to pretreat the exosome sample.

[0153] The manufacturer of the sample diluent is Aimejie Technology Co., Ltd., product number: ICT-647.

[0154] Test Case

[0155] Test Example 1: Effects of different pretreatment methods on exosomal KL-6 protein detection results

[0156] After extracting exosomes from serum KL-6-positive samples using a kit, the samples were diluted 2-fold and 4-fold with PBS buffer. The KL-6 protein content in the exosomes was then assayed using the detection methods provided in Examples 1-8 and Comparative Examples 1-6, respectively, on a fully automatic chemiluminescence immunoassay (model: Shine i2910). The dilution recovery was calculated based on the luminescence values ​​of the exosome stock solution, the 2-fold dilution, and the 4-fold dilution. After dilution, the samples were allowed to stand at room temperature for over 1 hour before being assayed simultaneously with the exosome stock solution.

[0157] Table 1 Effects of different pretreatment methods on the detection results of exosomal KL-6 protein

[0158] In combination with Examples 1-4, Comparisons 1-3, and Table 1, it can be seen that the dilution recovery of the reagent detection results for detecting exosome proteins using the pretreatment method of Examples 1-4 is significantly better than that of Comparative Examples 1-3, indicating that the dilution recovery of the reagent detection results for detecting exosome proteins using the pretreatment method of the present application is significantly better than that without pretreatment or using a conventional diluent or using a commercially available sample diluent; in the present application, by combining a non-lysing sample treatment solution in a specific concentration range, the incubation time can be further shortened, the detection efficiency and signal-to-noise ratio can be effectively improved, and fully automated detection of exosome proteins can be achieved.

[0159] In combination with Examples 5-8, Comparisons 4-6, and Table 1, it can be seen that the dilution recovery of the reagent detection results for detecting exosome proteins using the pretreatment method of Examples 5-8 is significantly better than that of Comparative Examples 4-6, indicating that the dilution recovery of the reagent detection results for detecting exosome proteins using the pretreatment method of the present application is significantly better than that without pretreatment or using a conventional diluent or using a commercially available sample diluent; in the present application, by combining a lysis-type sample processing solution in a specific concentration range, the incubation time can be further shortened, the detection efficiency and signal-to-noise ratio can be effectively improved, and fully automated detection of exosome proteins can be achieved.

[0160] When using the non-lysing sample treatment solution in this application to treat samples, the mixed sample must be incubated at the same time. When using the lysing sample pretreatment solution to pretreat the exosome sample, the next step can be performed without incubation.

[0161] Test Example 2: Comparison of test results between healthy subjects and ILD patient samples

[0162] Twenty samples of ILD-positive patients with a KL-6 test kit that was marketed, 20 samples of ILD-positive patients with a KL-6 test kit that was marketed, and 20 serum samples of healthy subjects were taken. The KL-6 protein content on exosomes was detected using the detection method provided in Example 1. ILD positivity was determined based on a comprehensive assessment of high-resolution CT (HRCT) and other clinical results. The test results are shown in Table 2 and Figure 1.

[0163] Table 2 Comparison of test results between healthy subjects and ILD patients

[0164] Data Analysis: Table 2 and Figure 1 show that the luminescence values ​​of KL-6 protein detected on exosomes from ILD-positive patients, whether those with commercially available serum KL-6 positive or those with commercially available serum KL-6 negative, were significantly higher than those detected on exosomes from samples from healthy individuals. Significant differences were observed between samples from patients with KL-6-positive ILD-positive serum and those from healthy individuals, as well as between samples from patients with KL-6-negative ILD-positive serum and those from healthy individuals (P<0.0001).

[0165] The above results show that for ILD-positive patients who cannot be effectively detected by serum KL-6 testing, the exosomal KL-6 protein detection method can identify the vast majority of them. The detection of interstitial pneumonia by KL-6 on exosomes has significantly higher sensitivity and specificity than that by serum KL-6 testing.

[0166] Test Example 3: Comparison of clinical compliance rates between serum KL-6 and exosome KL-6

[0167] The detection method provided in Example 1 was used to simultaneously detect serum samples and serum-extracted exosome samples from ILD-positive patients and healthy subjects (a total of 60 cases). The positive and negative samples were defined based on the clinical diagnosis of ILD. The ROC curves of serum KL-6 and exosome KL-6 test results were prepared respectively. The cutoff values ​​were determined based on the maximum value of Youden's index (sensitivity+specificity-1). ILD positive and negative properties were determined based on high-resolution CT (HRCT) and other clinical results. Test results are shown in Figure 2.

[0168] Data analysis: According to the results shown in Figure 2, the AUC (Area Under Curve) value of the exosome KL-6 test result is higher than the AUC value of the serum KL-6 test result, indicating that the exosome KL-6 test has a higher clinical compliance rate than the serum KL-6 test in the diagnosis of ILD. At the same time, the difference in AUC between the exosome KL-6 test and the serum KL-6 test is mainly reflected in the specificity. The exosome KL-6 test can reduce the influence of non-exosome KL-6 protein in the sample and other interferences in the blood, and has a higher specificity (lower cutoff) than the serum KL-6 test.

[0169] Test Example 4: Combination of Exosome KL-6 and Exosome CA125 for Diagnosis of Interstitial Lung Disease Based on the ROC curve of the exosome KL-6 detection results in Test Example 3, the cutoff of the exosome KL-6 detection kit was preliminarily determined. The CA125 exosome detection kit was prepared using the detection method provided in Example 9, and the samples in Test Example 2 were tested, and the preliminary cutoff was determined. According to the cutoff, the positive and negative results of the exosome CA125 and exosome KL-6 detection results of ILD patient samples were determined, and then the correlation between the positive and negative results of the exosome KL-6 and exosome CA125 detection results in Test Example 2 and the clinical symptoms of ILD patients was evaluated. The results are shown in Table 3.

[0170] Table 3 Diagnosis results of interstitial lung disease using combination of exosome KL-6 and exosome CA125

[0171] Results: Based on the ROC curve, the exosomal CA125 cutoff value was preliminarily determined to be 11053, and the exosomal KL-6 cutoff value was preliminarily determined to be 39102. A total of 14 samples were positive for both exosomal KL-6 and exosomal CA125, accounting for 82% (14 / 17) of all idiopathic pulmonary fibrosis (IPF) or severe pneumonia. A total of 16 samples were positive for exosomal KL-6 and negative for exosomal CA125, of which 3 were diagnosed with IPF or severe pneumonia, accounting for 18.7% (3 / 17) of all non-IPF or severe pneumonia samples.

[0172] These results indicate that combined diagnosis of exosomal KL-6 and exosomal CA125 can effectively identify the vast majority of IPF or severe pneumonia. The combined detection of exosomal KL-6 and exosomal CA125 may have important clinical value in differentiating interstitial pneumonia and assessing its severity.

[0173] It should be noted that the embodiments described above are only used to explain the present application and do not constitute any limitation to the present application. The present application has been described with reference to typical embodiments, but it should be understood that the words used therein are descriptive and explanatory words, rather than restrictive words. The present application may be modified as specified within the scope of the claims of the present application, and the invention may be revised without departing from the scope and spirit of the present application. Although the present application described therein relates to specific methods, materials and embodiments, it does not mean that the present application is limited to the specific examples disclosed therein. On the contrary, the present application can be extended to all other methods and applications with the same function.

Claims

1. Application of KL-6 protein on exosomes in the preparation of a kit for diagnosing lung diseases.

2. An application of KL-6 and CA125 on exosomes in the preparation of a kit for diagnosing lung diseases.

3. The use according to claim 1 or 2, characterized in that: The kit includes a sample processing solution; the sample processing solution is a lysis type sample processing solution or a non-lysis type sample processing solution.

4. The use according to claim 3, characterized in that: The lysis type sample processing solution includes the following raw materials in weight percentage: 0.5-2% of disodium hydrogen phosphate dodecahydrate, 0.5-2% of sodium dihydrogen phosphate dihydrate, 0.5-3.0% of NaCl, 0.5-3% of BSA, 0.05-1% of Triton X-100, 0.1-2% of anionic surfactant, 0.1-5% of zwitterionic surfactant, 0.1-2% of Tween-20, 0.02-0.1% of EDTA-2Na, 0.05-0.2% of sodium azide, and the rest is water.

5. The use according to claim 4, characterized in that: The anionic surfactant is at least one of sodium lauryl sulfate, sodium lauryl sarcosinate, and lithium lauryl sulfate; The zwitterionic surfactant is at least one of CHAPS, sodium lauroamphoacetate, sodium cocoamphoacetate, CHAPSO, SB3-14, SB3-12, SB3-10, and SB3-8.

6. The use according to claim 3, characterized in that: The non-lysing sample processing solution includes the following raw materials in weight percentage: 0.5-2% disodium hydrogen phosphate dodecahydrate, 0.5-2% sodium dihydrogen phosphate dihydrate, 0.5-3% NaCl, 0.5-3% BSA, 0.2-2% zwitterionic surfactant, 0.1-2% Tween-20, 0.02-0.1% EDTA-2Na, 0.05-0.2% sodium azide, and the rest is water.

7. The use according to claim 6, characterized in that: The zwitterionic surfactant is at least one of SB3-14, sodium lauroamphoacetate, sodium cocoamphoacetate, SB3-12, SB3-10, and SB3-8.

8. A kit for diagnosing lung diseases, characterized in that: The kit comprises the sample processing solution according to any one of claims 3 to 7, magnetic beads coated with capture antibodies, detection antibodies labeled with luminescent substances, luminescent substrates and protein calibrators.

9. A kit for diagnosing lung diseases according to claim 8, characterized in that: The capture antibody is a KL-6 capture antibody, and the detection antibody is a KL-6 detection antibody; or the capture antibody is a CA125 capture antibody, and the detection antibody is a CA125 detection antibody.

10. A method for detecting protein content in exosomes using the kit according to claim 8 or 9, characterized in that: The steps of the detection method are as follows: Before the exosome sample to be tested is tested, the exosome sample to be tested is pretreated, and the exosome sample to be tested is mixed with a sample treatment solution to obtain a pretreated exosome sample to be tested; Among them, the volume ratio of the exosome sample to be tested to the sample processing solution is 1:(2-30); The reaction time of the pretreatment is 1-120 min; the reaction temperature is 25-42°C.

Citation Information

Patent Citations

  • Method for detecting content of KL-6 protein on exosome and application thereof

    CN114113581A

  • Immunological detection method and reagent for SARS-cov-2

    JP2022174540A

  • Cancer detection markers

    WO2010065968A1